SCB-1019 / Sichuan Clover Biopharma - LARVOL DELTA

First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (clinicaltrials.gov) - P1 | N=192 | Recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults (clinicaltrials.gov) - P1 | N=160 | Completed | Sponsor: Clover Biopharmaceuticals AUS Pty | Recruiting ➔ Completed | N=60 ➔ 160 | Trial primary completion date: Oct 2024 ➔ Feb 2025

Enrollment change • Trial completion • Trial primary completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections

First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (clinicaltrials.gov) - P1 | N=192 | Not yet recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults (clinicaltrials.gov) - P1 | N=160 | Recruiting | Sponsor: Clover Biopharmaceuticals USA, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults (clinicaltrials.gov) - P1 | N=160 | Not yet recruiting | Sponsor: Clover Biopharmaceuticals USA, LLC

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

CLO-SCB-1019-003: Safety and Immunogenicity Study of SCB-1019T in Children (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd | N=112 ➔ 0 | Trial completion date: Jun 2026 ➔ Dec 2026 | Initiation date: Mar 2025 ➔ Oct 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Jan 2026 ➔ Jun 2026

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Trial withdrawal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity Study of SCB-1019T in Children (clinicaltrials.gov) - P1 | N=112 | Not yet recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections